Sign Out
1. Worsening of depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior may occur in both adult and pediatric. All patients being treated with antidepressants be appropriately monitored and closely observed for clinical worsening, suicidality, and unusual changes in behavior, particularly during initiation of therapy and during periods of dosage adjustments.
2. Suicide risks should be monitored in patients with SNRIs, regardless of the indication.
3. Desvenlafaxine succinate is not approved for use in pediatric patients.
